Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Total Liabilities: 2010-2025

Historic Total Liabilities for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $881.9 million.

  • Arrowhead Pharmaceuticals' Total Liabilities fell 7.05% to $881.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $881.9 million, marking a year-over-year decrease of 7.05%. This contributed to the annual value of $881.9 million for FY2025, which is 7.05% down from last year.
  • According to the latest figures from Q3 2025, Arrowhead Pharmaceuticals' Total Liabilities is $881.9 million, which was up 2.75% from $858.3 million recorded in Q2 2025.
  • Arrowhead Pharmaceuticals' 5-year Total Liabilities high stood at $957.6 million for Q4 2024, and its period low was $251.3 million during Q1 2022.
  • Moreover, its 3-year median value for Total Liabilities was $544.8 million (2024), whereas its average is $664.7 million.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Total Liabilities spiked by 493.98% in 2021 and then decreased by 19.26% in 2022.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Total Liabilities (Quarterly) stood at $266.0 million in 2021, then spiked by 86.15% to $495.1 million in 2022, then fell by 8.59% to $452.6 million in 2023, then soared by 111.59% to $957.6 million in 2024, then decreased by 7.05% to $881.9 million in 2025.
  • Its Total Liabilities stands at $881.9 million for Q3 2025, versus $858.3 million for Q2 2025 and $889.3 million for Q1 2025.